Acumen Pharmaceuticals Inc.

28/07/2024 | Press release | Distributed by Public on 28/07/2024 15:58

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.